RxDoctor Payments Data

Lauren McNally, NP

Nurse Practitioner · East Syracuse, NYNPI 1609362615

Payments from drug & device makers

$1,186in general payments, 2019–2025

Across 13 payments — averaging $91.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$250
  • E.r. Squibb & Sons, L.L.C.$186
  • Sanofi$181
  • Springworks Therapeutics, Inc.$113
  • Incyte Corporation$100
  • Johnson & Johnson$99
  • plus $257 from 4 others

What the payments were for

  • Food & beverage$98783%
  • Education$19917%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,186 in reported general payments places this provider in the 85th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$46,897
Medicare patients
249
Services billed
5,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib52$744,825
Lenalidomide43$544,338
JakafiRuxolitinib Phosphate30$439,658
BrukinsaZanubrutinib41$393,333
RevlimidLenalidomide18$308,453
IbrancePalbociclib15$231,607
PomalystPomalidomide11$196,301
TasignaNilotinib Hcl11$105,422
PromactaEltrombopag Olamine13$103,305
VenclextaVenetoclax12$68,751
EliquisApixaban45$41,120
XareltoRivaroxaban37$34,099
Enoxaparin Sodium13$11,097
ValacyclovirValacyclovir Hcl80$5,315
Exemestane12$3,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$100$439,65830 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$186$196,30111 claims
Johnson & JohnsonXarelto$99$34,09937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in East Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →